

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
Yes. A consultee raised that EGFR mutations are more commonly found in females and people with East Asian or Bangladeshi, Indian or Pakistani ethnicity.
2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
The committee cannot address issues of differing disease prevalence in a technology appraisal.
3. Has any change to the draft scope been agreed to highlight potential equality issues?
No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No.

Approved by Associate Director (name): Ian Watson

Date: 28 October 2024